Discontinuation due to therapy completion or feeling that the medication was no longer needed was more common in the AOM discontinuation group compared to the ADM group
Magnesium has a mild stool-softening effect and is generally well-tolerated
Most or all of these are common in women who are overweight: Ultra-processed foods Low fiber intake Low protein diets Imbalanced gut flora Lack of short-chain fatty acids Chronic inflammation Poor quality sleep Chronic stress or high cortisol Obesity Insulin resistance/prediabetes Poor vagal nerve function Aging The critical point here is that all but one of those factors are largely or totally within our control
The dual agonist approach represented by tirzepatide demonstrates that activating multiple complementary pathways produces superior results to targeting a single pathway, even when that single pathway works quite well on its own
It belongs to a family of hormones known as incretins, which are released after eating to help regulate your blood glucose levels and metabolism
Side Effects: There were no serious incidents of hypoglycaemia (too little blood sugar) reported, nor were there any maglinancies in the thyroid gland or reports persistent hyperglycaemia (too much blood sugar) 8% of patients across all Retatrutide groups collectively did not continue treatment because of an adverse event The most commonly reported adverse events in people taking Retatrutide were gastrointestinal in nature (constipation, diarrhea, vomiting, nasuea), were mild to moderate in severity, and happened more often in people taking larger doses of Retatrutide All in all, patients on Retatrutide experienced a dramatic improvement in insulin sensitivity and any observed side effects were not significantly different in severity, type or frequency compared to the Phase 2 trial for obesity
